Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 6kWORD 21k
3 May 2018
E-001017/2018(ASW)
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-001017/2018

The Commission is aware of the discrepancy between current levels of plasma collection in the EU and the growing demand for plasma derived medicinal products and recognises their importance for the treatment of EU patients.

The evaluation of the Union legislation on blood, tissues and cells is still ongoing. Stakeholders have raised the issue of plasma supply during the stakeholder consultation and it was discussed at both the stakeholder event(1) and during a June 2017 ad-hoc meeting between stakeholders and representatives of the EU's blood competent authorities(2). The views put forward will be taken into account for the final evaluation report. On the basis of the results of this exercise, the Commission will decide on the necessity to update and strengthen existing legislation.

In the EU Research and Innovation programme(3), the Commission supports a range of research to develop diagnostics and new, advanced therapies for rare diseases including diseases related to blood and plasma, such as haemophilia and multiple myeloma.

It should be noted that the current legislative framework at Union level does not prevent Member States from establishing or changing their national plasma collection programmes, provided the collection and testing of blood and plasma meet the quality and safety requirements of the Union legislation.

(1)https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/ev_20170920_sr_en.pdf
(2)https://ec.europa.eu/health/blood_tissues_organs/events_en#anchor1
(3)https://ec.europa.eu/programmes/horizon2020/

Last updated: 15 May 2018Legal notice